Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

-- Quarter Highlighted by Cinryze(TM) [C1 Inhibitor (human)] Commercial Launch --

EXTON, Pa., Feb. 24 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2008.

Key events since September 30, 2008 include:

Operational:

  • Closed on acquisition of Lev Pharmaceuticals, Inc. (Lev) in October 2008;
  • Initiated commercial launch of Cinryze for routine prophylaxis of hereditary angioedema (HAE);
  • Developed and successfully launched Cinryze patient access program, CinryzeSolutions(TM);
  • Launched new sales team in December for Cinryze;
  • Achieved net Vancocin(R) sales of $50 million during fourth quarter 2008; and
  • Increased research and development expenses by 70 percent over the fourth quarter of 2007, primarily driven by maribavir and Cinryze.

Development:

  • Filed supplemental Biologics License Application (sBLA) for Cinryze for treatment of acute attacks of HAE;
  • Granted priority review by the U.S. Food and Drug Administration for Cinryze sBLA for treatment of acute attacks of HAE, with a Prescription Drug User Fee Act (PDUFA) date of June 3, 2009; and
  • Discontinued maribavir clinical development program for prophylaxis against cytomegalovirus disease in transplant patients based on the preliminary analysis of phase 3 data.

Financial Results:

  • Achieved 16th consecutive quarter of positive cash flows from operations; and
  • Ended 2008 with working capital of $305 million, which includes cash, cash equivalents and short-term investments of $276 mi
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Barrington, MA (PRWEB) October 25, 2014 ... control products, is pleased to announce the release ... achieve the highest level of contamination containment in ... ISO Class 3 and higher cleanroom environments, ValuSeal® ... filament polyester knit laundered wiper that continues Berkshire’s ...
(Date:10/25/2014)... , Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ... at the Fourth International Symposium on Thymosins in Health ... "When thymosin beta 4 (TB4) linked ... the peritoneal cavity in a rodent model of stroke, ... the brain parenchyma (the functional tissue of the brain). ...
(Date:10/25/2014)... ... the addition of the  "The Global Market ... Nanomaterials "  report to their offering.  ... graphene are the strongest, lightest and most ... performance-per-weight greater than any other material. In ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... 20 years of commercial life sciences sales experience to Cyntellect ... 21 Cyntellect, a privately-held life sciences company leading the ... announced today that it has appointed Andre Lubarsky as the ... responsible for the sales of Cyntellect,s cell purification and cell ...
... LCAV ), a leading provider of laser vision ... of Michael J. Celebrezze,to the position of Chief Financial ... Mr. Celebrezze, who has served as interim CFO since ... as Senior Vice,President of Finance and Treasurer in July ...
... GPRO ),CE-marked APTIMA(R) HPV assay may ... detect high-risk human papillomavirus (HPV) infections that are,associated ... nine,oral presentations and two scientific posters presented last ... conference of the,European Research Organization on Genital Infection ...
Cached Biology Technology:Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America 2LCA-Vision Names Michael J. Celebrezze CFO 2LCA-Vision Names Michael J. Celebrezze CFO 3LCA-Vision Names Michael J. Celebrezze CFO 4Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 2Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 3Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 4Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 5
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
(Date:10/16/2014)... Although monocultures can be cultivated efficiently, they are ... water caused by monoculture cultivation is becoming increasingly ... principal crop form and are regarded as the ... production – quite wrongfully, finds Bernhard Schmid, an ... advocates a novel form of agriculture and forestry. ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... highly detailed study, Tecnalia has calculated the carbon footprint of ... from the field work right up to the end of ... the piece of information that allows one to know the ... has enabled the Grupo Faustino to be the first winery ...
... After outgrowing teenage infatuations with the girl next door, ... amorous attractions to the wife next door, according to ... testosterone levels dropped when they were interacting with the ... mechanisms that keep men from constantly competing for each ...
... (ACMG) released the widely-anticipated "ACMG Recommendations for Reporting of ... at its 2013 Annual Clinical Genetics Meeting today in ... one of the largest gatherings of medical and health ... and genome sequencing become more commonly used in medical ...
Cached Biology News:Tecnalia has calculated the carbon footprint of some wines 2Men may have natural aversion to adultery with friends' wives 2ACMG releases report on incidental findings in clinical exome and genome sequencing 2ACMG releases report on incidental findings in clinical exome and genome sequencing 3
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: